SARASOTA, FL (January 28, 2020) – Biolife, LLC, developer and manufacturer of StatSeal® and WoundSeal® hemostatic products, is launching new patent pending technology improvements of both products in the first quarter of 2020. The core ingredient in all Biolife products is a revolutionary powder that stops bleeding quickly by forming an instant occlusive seal or scab over wounds and vascular access sites.

As a medical device manufacturer, Biolife monitors and evaluates customer feedback on an ongoing basis. Although feedback from customers across industries is overwhelmingly favorable regarding product safety and efficacy, some customers voiced that the dark brown powder could be “less messy” and “look better.” This feedback was the genesis of the development of the first StatSeal disc product, which was launched in 2013. However, even with the availability of the StatSeal disc product line, some users prefer powder over disc because of its versatile nature in a clinical setting. Based on this feedback, Biolife’s Research and Development Department set out to make improvements to the existing powder.

The improved, patent pending StatSeal and WoundSeal products are currently in launch phase. “We’re constantly striving to innovate our products to meet the dynamic needs of our growing customer base,” states Stuart Jones, Chief Executive Officer at Biolife. Powder enhancements include improved aesthetics that are similar in appearance to makeup powder, and a finer texture which is less messy and adheres better to the wound or access site. The powder delivery vehicle for StatSeal products was converted from a bottle to an easy-pour tube. The long-nosed spout provides improved powder pouring accuracy to the site, and helps clinicians achieve a cleaner, neater dressing on the patient. The same patent pending powder is utilized in the production of all StatSeal disc products, which are made of compressed powder and encased in a white medical grade foam.

Response to the improved powder launch has been very positive. “Integrating StatSeal products into our patient recovery protocol has improved patient care, increased staff efficiency and streamlined our discharge process. The StatSeal product improvements make it even easier for our staff to use,” said Matheen Khuddus, MD, FACC, FSCAI of the Cardiac and Vascular Institute in Gainesville, Florida.

Product interest continues to grow worldwide as product safety and efficacy is recognized by key opinion leaders, like Khuddus, who embrace Biolife products as state-of-the-art technology that helps improve patient quality of life, and in some instances, helps save patient lives. In 2019 alone, there were eight investigator-initiated studies published on Biolife’s product efficacy.